Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Clinical Microbiology & Infectious Diseases
Published in: European Journal of Clinical Microbiology & Infectious Diseases 2/2017

01-02-2017 | Review

Population attributable burden of Helicobacter pylori-related gastric cancer, coronary heart disease, and ischemic stroke in China

Authors: J. Jiang, Y. Chen, J. Shi, C. Song, J. Zhang, K. Wang

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 2/2017

Login to get access

Abstract

Helicobacter pylori, a risk factor of cancer and chronic diseases, remains highly prevalent in China. This review aims to systematically evaluate the H. pylori-attributable burden for gastric cancer (GC), coronary heart disease (CHD), and ischemic stroke (IS) in the Chinese population. Helicobacter pylori prevalence was updated by pooling the results reported in studies across China. The population attributable fraction (PAF) was calculated based on the H. pylori prevalence 10 years ago and relative risks of specific disease by reviewing the prospective studies published from 2000 through 2015. In China, the nationwide average prevalence of H. pylori was estimated to be 42.06 % in the general population during 2009–2013. The fixed effects pooled relative risk (RR) of 1.89 [95 % confidence interval (CI): 1.57–2.26] was obtained for gastric cancer and H. pylori infection. Helicobacter pylori infection was responsible for around 37.38 % of noncardia GC, corresponding to about 105,536 cases in 2012. As for extra-gastric disorders, H. pylori infections had higher risk of CHD (RR = 1.55, 95 % CI: 1.37–1.76) and IS (RR = 1.54, 95 % CI: 1.42–1.66). About 23.15 % of CHD and 22.29 % of IS were attributable to H. pylori infection. The estimates of H. pylori-attributable burden reveal a great potential of reducing H. pylori-related chronic disease burden by H. pylori eradication. Large prospective studies are warranted to identify which H. pylori strains, which subtypes of the disease, and which subgroups of the population have the greatest risk of relevant diseases and the effect of H. pylori eradication on the prevention of H. pylori-related diseases.
Appendix
Available only for authorised users
Literature
1.
de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D et al (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13:607–615CrossRefPubMed
2.
Xiang W, Shi JF, Li P, Wang JB, Xu LN, Wei WQ et al (2011) Estimation of cancer cases and deaths attributable to infection in China. Cancer Causes Control 22:1153–1161CrossRefPubMed
3.
Censini S, Lange C, Xiang Z, Crabtree JE, Ghiara P, Borodovsky M et al (1996) cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A 93:14648–14653CrossRefPubMedPubMedCentral
4.
Møller H, Heseltine E, Vainio H (1995) Working group report on schistosomes, liver flukes and Helicobacter pylori. Int J Cancer 60:587–589CrossRefPubMed
5.
Zullo A, Hassan C, Ridola L, Repici A, Manta R, Andriani A (2014) Gastric MALT lymphoma: old and new insights. Ann Gastroenterol 27:27–33PubMedPubMedCentral
6.
Sun J, Rangan P, Bhat SS, Liu L (2016) A meta-analysis of the association between Helicobacter pylori infection and risk of coronary heart disease from published prospective studies. Helicobacter 21:11–23CrossRefPubMed
7.
Cremonini F, Gabrielli M, Gasbarrini G, Pola P, Gasbarrini A (2004) The relationship between chronic H. pylori infection, CagA seropositivity and stroke: meta-analysis. Atherosclerosis 173:253–259CrossRefPubMed
8.
9.
Chmiela M, Gajewski A, Rudnicka K (2015) Helicobacter pylori vs coronary heart disease—searching for connections. World J Cardiol 7:187–203PubMedPubMedCentral
10.
Huang WS, Tseng CH, Lin CL, Tsai CH, Kao CH (2014) Helicobacter pylori infection increases subsequent ischemic stroke risk: a nationwide population-based retrospective cohort study. QJM 107:969–975CrossRefPubMed
11.
Lai CY, Yang TY, Lin CL, Kao CH (2015) Helicobacter pylori infection and the risk of acute coronary syndrome: a nationwide retrospective cohort study. Eur J Clin Microbiol Infect Dis 34:69–74CrossRefPubMed
12.
Monzón H, Forné M, Esteve M, Rosinach M, Loras C, Espinós JC et al (2013) Helicobacter pylori infection as a cause of iron deficiency anaemia of unknown origin. World J Gastroenterol 19:4166–4171CrossRefPubMedPubMedCentral
13.
Marietti M, Gasbarrini A, Saracco G, Pellicano R (2013) Helicobacter pylori infection and diabetes mellitus: the 2013 state of art. Panminerva Med. 55:277–281PubMed
14.
Khamechian T, Movahedian AH, Ebrahimi Eskandari G, Heidarzadeh Arani M, Mohammadi A (2015) Evaluation of the correlation between childhood asthma and Helicobacter pylori in Kashan. Jundishapur J Microbiol 8, e17842CrossRefPubMedPubMedCentral
15.
Chang SS, Hu HY (2014) No inverse relationship between Helicobacter pylori infection and adult asthma with peptic ulcer disease. Hepatogastroenterology 61:529–534PubMed
16.
Vasapolli R, Malfertheiner P, Kandulski A (2016) Helicobacter pylori and non-malignant upper gastrointestinal diseases. Helicobacter 21(Suppl 1):30–33CrossRefPubMed
17.
18.
Zhang WD, Hu FL, Xiao SD, Xu ZM (2010) Prevalence of Helicobacter pylori infection in China. Mod Digest Interv 15:265–270
19.
Levin ML (1953) The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum 9:531–541PubMed
20.
Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M et al (2010) The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. The Ottawa Hospital Research Institute
21.
22.
Kamangar F, Qiao YL, Blaser MJ, Sun XD, Katki H, Fan JH et al (2007) Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br J Cancer 96:172–176CrossRefPubMed
23.
Epplein M, Zheng W, Xiang YB, Peek RM Jr, Li H, Correa P et al (2012) Prospective study of Helicobacter pylori biomarkers for gastric cancer risk among Chinese men. Cancer Epidemiol Biomarkers Prev 21:2185–2192CrossRefPubMedPubMedCentral
24.
Ma JL, Zhang L, Pan KF, Liu WD, Feng GS, You WC (2005) Helicobacter pylori and the progression of gastric cancer: a 10-year cohort study. Natl Med J China 85:2758–2761
25.
Zhang X, Xue L, Xing L, Wang J, Cui J, Mi J et al (2012) Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community. Int J Cancer 130:1614–1619CrossRefPubMed
26.
Wang RT, Wang T, Chen K, Wang JY, Zhang JP, Lin SR et al (2002) Helicobacter pylori infection and gastric cancer: evidence from a retrospective cohort study and nested case–control study in China. World J Gastroenterol 8:1103–1107CrossRefPubMedPubMedCentral
27.
Hsu WY, Lin CH, Lin CC, Sung FC, Hsu CP, Kao CH (2014) The relationship between Helicobacter pylori and cancer risk. Eur J Intern Med 25:235–240CrossRefPubMed
28.
Liu XH (2005) Relation between Helicobacter pylori infection and risk factors of coronary heart disease. J Pract Diagn Ther 19:881–883
29.
Lu SY, Guo QH, Liu JS, Xie SZ, Li L, Sun YC et al (2003) The relative study of coronary heart disease and Helicobacter pylori. Med J Chin People Health 15:67–68
30.
Qiao ZF, Hong Y, Zhou L (2010) Investigation on the association between Helicobacter pylori infection and coronary heart disease. Hainan Med J 21:38–40
31.
Wang C, Liu YB, Han ML (2014) Research on correlation between Helicobacter pylori infection and coronary heart disease. Chin J Nosocomiol 24:3526–3527
32.
Wang YP, Yan SQ, Tian HN, Jing H (2008) Correlation between Helicobacter pylori infection and coronary heart disease. Chin J Diffic Compl Cases 7:74–76
33.
Lai YQ, Yang XL, Li M, Hu H, Yang G (2005) Study on relationship between Helicobacter pylori IgG antibody components and coronary heart disease. Chin J Pract Intern Med 25:241–242
34.
Wang Y, Shen J, Yan S, Tian H, Jing H (2008) Correlation between Helicobacter pylori infection and coronary heart disease. Chin J Diffic Compl Cases 7:74–76
35.
Cao PL, Liu XQ, Tang QZ, Liu Y, Wang XQ (2011) Correlation between different Helicobacter pylori genotypes and coronary heart disease. China Med Her 24–26
36.
Chuai Y, Song H, Xue M, Ning X, He Z, Li Y et al (2012) Relationship between Helicobacter pylori infection and coronary artery disease. Chin Heart J 24:57–59
37.
Dian Q, Guo T, Liu Z, Liu R, Li C (2014) Correlation between coronary stenosis and lipid metabolism and Helicobacter pylori infection. Chin J Nosocomiol 24:6144–6146
38.
Zhang J, Xun Y, Gai J, Li Y (2008) The relationship between Helicobacter pylori infection and risk factors associated with coronary heart disease. Chin J Prim Med Pharm 15:1686
39.
Wang WY, Yang PH, Cao YY, Liu F, Ma B (2013) Relation between Helicobacter pylori infection and coronary heart disease. Chin Heart J 21:609–610
40.
Guan XR, Jiang LX, Ma XH, Wang LF, Quan H, Li HY (2010) Respiratory syncytial virus infection and risk of acute myocardial infarction. Am J Med Sci 340:356–359CrossRefPubMed
41.
Liu MY (2011) Relationship between Helicobacter pylori infection and coronary heart disease. Chin J Nosocomiol 21:1599–1601
42.
Deng X, Chen X, Li B (2005) Matching case–control study of the relation between Helicobacter pylori and coronary heart disease. J Nanhua Univ(Med Ed) 33:499–500
43.
Qu W (2012) Research on the correlation of Helicobacter pylori infection in patients with coronary heart disease. China Med Herald 9:49–50
44.
Tian F, Hu D, Sun X, Ge J, Ma J, Wang J et al (2004) The relation between coronary heart disease and chronic infection of microorganism. Tianjin Med J 32:554–556
45.
Zeng Z, Huang MH, Liang YJ, Zhang Q, Jiang T, Liu YG (2000) Preliminary exploration of the association between Helicobacter pylori infection and coronary heart disease. China J Mod Med 10:27–28
46.
Liu DN, He ZY, Li JS (2003) Relation between Helicobacter pylori infection and acute myocardial infarction. Chin J Arterioscler 11:541–544
47.
Lu YL, Pan WQ (2015) Association between Hp infection and first cardio-cerebrovascular events in elderly hypertensive patients. Chin J Geriatr Heart Brain Vessel Dis 17:130–132
48.
Hao R, Tian J (2013) Studies on correlation between acute cerebral infarction and Helicobacter pylori. Pharma Care Res 13:404, 432, 466CrossRef
49.
Yu Z (2011) Correlation between cerebral infarction and Helicobacter pylori infection. Guide China Med 09:285–287
50.
Shu AM, Zhou YA (2006) The study on relationship between acute cerebral infarction and chronic Helicobacter pylori (Hp) infection with 13C-UREA-Breath test. J Hebei North Univ (Med Ed) 23:3–6
51.
Zhang A, Wang Y, Zhu K (2009) Relationship between the infection of Helicobacter pylori and ischemic stroke. J Neurol Neurorehabil 6:187–190
52.
Wang YS, Jiao J, Wang G (2003) Analysis of Helicobacter pylori infection in patients with acute myocardial infarction patients. Chin J Gerontol 23:716–717
53.
Wei ZH, He D, Zeng ZJ (2014) Situation of Helicobacter pylori infection in patients with cerebral infarction and its effect on high-sensitivity C-reactive protein and blood lipid metabolism. Guangxi Med J 36:335–337
54.
Wu HQ, Zhang X, Tang Y (2012) Association of Helicobacter pylori infection and serum homocysteine level in patients with cerebral infarction. J Zhejiang Univ (Med Sci) 41:89–92
55.
Wu XX, Huang ZY, Huang DH (2003) Study on the relationship between Helicobacter pylori infection and cerebral infarction. Chin J Prim Med Pharm 10:599–600
56.
Zhang X (2007) Study on the relationship between Helicobacter pylori infection and cerebral infarction. Med Inf 20:872–873
57.
Zhang Q, Zhang RB, Meng X (2008) Relationship between Helicobacter pylori infection and transient ischemic attack as well as cerebral infarction. Shandong Med J 48:29–30
58.
Zhao M (2012) Correlation between Helicobacter pylori infection and cerebral infarction. Chin J Nosocomiol 22:3273–3274
59.
Dou YC, Li X, Leng X (2008) Prevalence of H. pylori infection in cerebral infarction patients and the association between H. pylori infection and cerebral infarction. Chin J Lab Diagn 12:352–354
60.
Duan HL, Shi LX, Chen YC, Wang YL (2005) A study on relationship between Helicobacter pylori infection and cerebral hemorrhage and cerebral infarction. J North China Coal Med Coll 7:557–558
61.
Su Z, Pang Y (2007) Relation of Helicobacter pylori infection and coronary heart disease. J Pract Med 23:3019–3021
62.
Zhou GA, Zhang FY, Wang AM (2013) The influence of Helicobacter pylori infection to cerebral infarction of different subtype. J Commun Med 11:33–34
63.
Li XH, Yin L, Liu P (2007) The relationship between cytotoxin-associated gene-A positive Helicobacter pylori strains infection and cerebral infarction. Int J Cerebrovasc Dis 15:455–459
64.
Xu F, Zhu B (2013) Study on correlation between Helicobacter pylori infectis and high sensitive C reactive protein in patients with ischemic stroke. Chin J Nosocomiol 23:3645–3646
65.
Yang X, Gao Y, Zhao X, Tang Y, Su Y (2011) Chronic Helicobacter pylori infection and ischemic stroke subtypes. Neurol Res 33:467–472CrossRefPubMed
66.
Wang KJ, Wang RT (2003) Meta-analysis on the epidemiology of Helicobacter pylori infection in China. Chin J Epidemiol 19–22
67.
Helicobacter and Cancer Collaborative Group (2001) Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49:347–353CrossRef
68.
Doorakkers E, Lagergren J, Engstrand L, Brusselaers N (2016) Eradication of Helicobacter pylori and gastric cancer: a systematic review and meta-analysis of cohort studies. J Natl Cancer Inst 108. pii: djw132
69.
Liu J, Wang F, Shi S (2015) Helicobacter pylori infection increase the risk of myocardial infarction: a meta-analysis of 26 studies involving more than 20,000 participants. Helicobacter 20:176–183CrossRefPubMed
70.
Wang ZW, Li Y, Huang LY, Guan QK, Xu DW, Zhou WK et al (2012) Helicobacter pylori infection contributes to high risk of ischemic stroke: evidence from a meta-analysis. J Neurol 259:2527–2537CrossRefPubMed
71.
Zhang S, Guo Y, Ma Y, Teng Y (2008) Relationship between the cytotoxin-associated gene-A status of H pylori strains and cerebral infarction in European Caucasians and Chinese Han: a meta-analysis. World J Gastroenterol 14:1286–1292CrossRefPubMedPubMedCentral
72.
Chen J, Bu XL, Wang QY, Hu PJ, Chen MH (2007) Decreasing seroprevalence of Helicobacter pylori infection during 1993–2003 in Guangzhou, southern China. Helicobacter 12:164–169CrossRefPubMed
73.
Zhang DH, Zhou LY, Lin SR, Ding SG, Huang YH, Gu F et al (2009) Recent changes in the prevalence of Helicobacter pylori infection among children and adults in high- or low-incidence regions of gastric cancer in China. Chin Med J (Engl) 122:1759–1763
74.
Pan KF, Zhang L, Gerhard M, Ma JL, Liu WD, Ulm K et al (2016) A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. Gut 65:9–18CrossRefPubMed
75.
Liu WZ, Xie Y, Cheng H, Lu NH, Hu FL, Zhang WD et al (2013) Fourth Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis 14:211–221CrossRefPubMed
76.
Everhart JE (2000) Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin North Am 29:559–578CrossRefPubMed
77.
Shi RH, Xu SF, Zhang HJ, Ding YB, Sun GQ, Huang XY et al (2008) Prevalence and risk factors for Helicobacter pylori infection in Chinese populations. Helicobacter 13:157–165CrossRefPubMed
78.
Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM (2001) Association of H. pylori infection with gastric carcinoma: a meta analysis. World J Gastroenterol 7:801–804CrossRefPubMedPubMedCentral
79.
Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH (2003) Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 125:1636–1644CrossRefPubMed
80.
Karnes WE Jr, Samloff IM, Siurala M, Kekki M, Sipponen P, Kim SW et al (1991) Positive serum antibody and negative tissue staining for Helicobacter pylori in subjects with atrophic body gastritis. Gastroenterology 101:167–174CrossRefPubMed
81.
Colquhoun A, Arnold M, Ferlay J, Goodman KJ, Forman D, Soerjomataram I (2015) Global patterns of cardia and non-cardia gastric cancer incidence in 2012. Gut 64:1881–1888CrossRefPubMed
82.
83.
Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P (2014) Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 348:g3174CrossRefPubMedPubMedCentral
84.
Lee YC, Chiang TH, Chou CK, Tu YK, Liao WC, Wu MS et al (2016) Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 150:1113–1124.e5CrossRefPubMed
85.
Yeh JM, Kuntz KM, Ezzati M, Goldie SJ (2009) Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. Int J Cancer 124:157–166
86.
Rothenbacher D, Brenner H (2003) Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications. Microbes Infect 5:693–703CrossRefPubMed
Metadata
Title
Population attributable burden of Helicobacter pylori-related gastric cancer, coronary heart disease, and ischemic stroke in China
Authors
J. Jiang
Y. Chen
J. Shi
C. Song
J. Zhang
K. Wang
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 2/2017
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-016-2810-x

Other articles of this Issue 2/2017

European Journal of Clinical Microbiology & Infectious Diseases 2/2017 Go to the issue

Original Article

Determinants for persistence of Pseudomonas aeruginosa in hospitals: interplay between resistance, virulence and biofilm formation

Original Article

Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013–2014 at the Geneva University Hospitals

Original Article

Technical and clinical validation of three commercial real-time PCR kits for the diagnosis of neuroborreliosis in cerebrospinal fluid on three different real-time PCR platforms

Original Article

Drug concentrations in the serum and cerebrospinal fluid of patients treated with norvancomycin after craniotomy

Original Article

Characteristics of cefazolin inoculum effect-positive methicillin-susceptible staphylococcus aureus infection in a multicentre bacteraemia cohort

Original Article

Abnormal vaginal flora in symptomatic non-pregnant and pregnant women in a Greek hospital: a prospective study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits